Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?
作者： Darshan Shah , Stacy Brown , Nick Hagemeier , Shimin Zheng , Amy Kyle
DOI: 10.1186/S40064-016-2576-8
关键词: Opioid 、 Neonatal abstinence 、 Anesthesia 、 Pregnancy 、 Cord blood 、 Opioid use 、 Population 、 Buprenorphine 、 Metabolite 、 Medicine
摘要: Background Buprenorphine is a semi-synthetic opioid used for the treatment of dependence. Opioid use, including buprenorphine, has been increasing in recent years, general population and pregnant women. Consequently, there rise frequency neonatal abstinence syndrome (NAS), associated with buprenorphine use during pregnancy. The purpose this study was to investigate correlations between buprenorphine-metabolite concentrations cord blood onset NAS exposed newborns.
etsu.edu
springeropen.com
core.ac.uk
springer.com
paperity.org参考文章(31)
Hendrée E. Jones, Gabriele Fischer, Sarah H. Heil, Karol Kaltenbach, Peter R. Martin, Mara G. Coyle, Peter Selby, Susan M. Stine, Kevin E. O'Grady, Amelia M. Arria, Maternal Opioid Treatment: Human Experimental Research (MOTHER)--approach, issues and lessons learned. Addiction. ,vol. 107, pp. 28- 35 ,(2012) , 10.1111/J.1360-0443.2012.04036.X
Amy Redmond Kyle, Jennifer Carmical, Darshan Shah, Jason Pryor, Stacy Brown, UHPLC‐MS/MS quantification of buprenorphine, norbuprenorphine, methadone, and glucuronide conjugates in umbilical cord plasma Biomedical Chromatography. ,vol. 29, pp. 1567- 1574 ,(2015) , 10.1002/BMC.3460
T Lewis, J Dinh, JS Leeder, Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research Clinical Pharmacology & Therapeutics. ,vol. 98, pp. 309- 320 ,(2015) , 10.1002/CPT.159
Antoine Malek, Donald R. Mattison, Drugs and medicines in pregnancy: the placental disposition of opioids. Current Pharmaceutical Biotechnology. ,vol. 12, pp. 797- 803 ,(2011) , 10.2174/138920111795470859
Alane B. O’Connor, Liam O’Brien, William A. Alto, Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy? Journal of Perinatal Medicine. ,vol. 0, pp. 1- 3 ,(2013) , 10.1515/JPM-2012-0288
Teresa Gray, Marilyn Huestis, Bioanalytical procedures for monitoring in utero drug exposure. Analytical and Bioanalytical Chemistry. ,vol. 388, pp. 1455- 1465 ,(2007) , 10.1007/S00216-007-1228-9
SL Kacinko, HE Jones, RE Johnson, RE Choo, MA Huestis, Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clinical Pharmacology & Therapeutics. ,vol. 84, pp. 604- 612 ,(2008) , 10.1038/CLPT.2008.156
Marta Concheiro, Diaa M. Shakleya, Marilyn A. Huestis, Simultaneous Quantification of Buprenorphine, Norbuprenorphine, Buprenorphine-Glucuronide and Norbuprenorphine-Glucuronide in Human Umbilical Cord by Liquid Chromatography Tandem Mass Spectrometry Forensic Science International. ,vol. 188, pp. 144- 151 ,(2009) , 10.1016/J.FORSCIINT.2009.04.005
Isabelle Lacroix, Alain Berrebi, Daniel Garipuy, Laurent Schmitt, Yamina Hammou, Catherine Chaumerliac, Maryse Lapeyre-Mestre, Jean-Louis Montastruc, Christine Damase-Michel, Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. European Journal of Clinical Pharmacology. ,vol. 67, pp. 1053- 1059 ,(2011) , 10.1007/S00228-011-1049-9
Alexander Elkader, Beth Sproule, Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinectics. ,vol. 44, pp. 661- 680 ,(2005) , 10.2165/00003088-200544070-00001